Cross-Country Collaborations, Business As Usual?
Pharmaceutical companies cannot afford to ignore the growing number of cross-country collaborations springing up in Europe aimed at securing more affordable medicines through actions such as jointly negotiated pricing deals. In Vivo looks at the factors that may influence the rise or fall of these collaborations and at how they may eventually make companies rethink the way they do business.
You may also be interested in...
The BeNeLuxAI initiative was among the many topics covered at the DIA Europe 2019 conference in Austria last week. The cross-country coalition has some new drugs in its sights for joint pricing talks and the conference was given an insight into the workings of the collaboration by a Belgian health department advisor close to the initiative.
How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants interviewed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.
ANVISA, Brazil’s medicines regulator, is asking for feedback on the regulatory pathway for biosimilars.